PharmaShots

MSD Signs a License Agreement with King’s College London & Wellcome’s Innovations to Develop Chronic Neuropathic Pain Therapies

MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

September 24, 2019September 24, 2019Tuba Khan

Shots: MSD to supply Keytruda (pembrolizumab) to I-Mab to utilize it in clinical studies in combination with its TJC4. The companies will collaborate [Read More...]

Vertex Enters into an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

Vertex Signs an Access Agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

September 12, 2019September 12, 2019Tuba Khan

Shots: The access agreement allows patients with eligible cystic fibrosis to access Orkambi and Symkevi (tezacaftor/ivacaftor) in combination with ivacaftor in Scotland Vertex [Read More...]

Hansoh Enters into a Collaboration with Atomwise for AI-Based Drug Discovery

September 12, 2019September 12, 2019Tuba Khan

Shots: Atomwise to receive technology access fees, option exercise fees, royalties, and income-based on sublicensing or sale of assets leading to a total [Read More...]

Alexion Enters into an Exclusive License Agreement with Eidos to Develop and Commercialize AG10 in Japan

September 10, 2019September 10, 2019Tuba Khan

Shots: Eidos to receive $25M upfront, $25 equity investment at a premium to the market price upon deal execution, milestone and royalties. Alexion [Read More...]

Novartis Signs an Exclusive Research and Option to Acquire Agreement with IFM Due to Develop Therapies Targeting cGAS/STING Pathway

September 5, 2019September 5, 2019Tuba Khan

Shots: Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development [Read More...]

Boehringer Ingelheim Enters into a Licensing Agreement with Lupin to Expand its KRAS Cancer Program

September 4, 2019September 4, 2019Tuba Khan

Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim [Read More...]

Celltrion and Teva’s Herzuma (trastuzumab-pkrb, Herceptin biosimilar) Receives FDA’s Approval for HER2-Overexpressing Breast Cancer

Celltrion Enters into a Contract to Manufacture Agreement for its Remsima (biosimilar, infliximab) with Lonza

September 4, 2019September 4, 2019Tuba Khan

Shots: Celltrion has picked to manufacture its biosimilar Remsima’s drug substance at Lonza’s Singapore facility to supply it in American and European markets [Read More...]

Helsinn Enters into an Exclusive Distribution and License Agreement with Blanver and Varifarma for Pracinostat in South America

September 3, 2019September 3, 2019Tuba Khan

Shots: Blanver to register, promote, distribute & commercialize Pracinostat in Brazil while Varifarma to get rights in Argentina, Bolivia, Chile, Colombia, Ecuador, Paraguay, [Read More...]

Orexo Enters into an Agreement with GAIA to Develop and Commercialize Digital Therapy for Opioid Use Disorder

August 21, 2019August 21, 2019Tuba Khan

Shots: GAIA to receive royalties, milestone and financial compensation during the development phase. Orexo to get exclusive WW rights to commercialize DTx (OXD-01) [Read More...]

Biotheus Enters into an Antibody Agreement with Alligator Bioscience in Greater China

Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China

August 21, 2019August 21, 2019Tuba Khan

Shots: Alligator to receive ~52M in development milestones including $1M up front, $90M as option fee and royalties on sales and share of [Read More...]